Angela Lamarca: 5FU-based Adjuvant chemotherapy for Biliary Malignancies
Angela Lamarca, Consultant Medical Oncologist at Jiménez Díaz Foundation University Hospital and The Christie NHS Foundation Trust, shared a post on X by Erman Akkus, Medical Oncology Fellow at Ankara University, about a paper they authored, published in European Journal of Cancer:
“5FU-based Adjuvant chemotherapy for Biliary Malignancies.
Wondering, ‘Did we not know this? What is new?’
We looked at ‘short-term’ (2-y) HR (+’full-time’ HR)
Current SOC mostly beneficial at 2-y, later benefit ‘dilutes’
2-y HR: to be looked at in future trials.”
Quoting Erman Akkus’s post:
“Our study on adjuvant chemotherapy in biliary tract cancers has been published!
I am very thankful to Angela Lamarca for her great mentoring and support along the way.
5FU-based ChT:
RFS and OS benefit in both short and long terms
Benefit is apparent in short-term
No significant benefit with gemcitabine-based ChT.”
Authors: Angela Lamarca and Erman Akkus.
More posts featuring Angela Lamarca and Erman Akkus.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023